---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-001714"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2023-01-17T23:59:59+00:00"
generated_at: "2026-06-20T14:43:10.770070+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Angion merges with Elicio in all-stock deal; Elicio holders to own 65.5% of combined company

## Summary
- Elicio stockholders will own 65.5% and Angion stockholders 34.5% of combined company on a fully-diluted basis.
- Combined company to focus on Elicio's ELI-002 therapeutic cancer vaccine targeting mKRAS-driven tumors, currently in Phase 1 trial.
- Angion committed up to $10M bridge loan to Elicio in two installments; merger expected to close in Q2 2023.
- Robert Connelly, CEO of Elicio, will be CEO of combined company; board will have 9 directors with 6 from Elicio and 3 from Angion.
- Angion adopted retention bonus plan for CEO and CBO, providing cash bonuses and accelerated equity vesting upon closing.

## SEC filing metadata
- accession: 0001140361-23-001714
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2023-01-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000114036123001714/0001140361-23-001714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000114036123001714/ny20006674x1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-001714
- JSON: https://secwatch.observer/filing/0001140361-23-001714.json
- Plain text: https://secwatch.observer/filing/0001140361-23-001714.txt

## Key facts
- Material Agreements
  Elicio Therapeutics, Inc. entered into Agreement and Plan of Merger and Reorganization with Angion Biomedica Corp. (effective 2023-01-17).
  - Action: entry
  - Agreement: merger
  - Counterparty: Angion Biomedica Corp.
  - Effective: 2023-01-17
  source text: On January 17, 2023, Angion Biomedica Corp. , a Delaware corporation (“Angion”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Elicio Therapeutics, Inc., a Delaware corporation (“Elicio”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601485/000114036123001714/0001140361-23-001714-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.